Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves’ Disease
Table 2
Comparison between patients of different outcome groups after the first RAI treatment.
Hypothyroid
Euthyroid
Hyperthyroid
Number of patients
59 (60.2%)
16 (16.3%)
23 (23.5%)
Age, years
43.5 ± 13.5
50.1 ± 17.0
41.4 ± 12.4
0.149
Sex (male : female)
22 : 37
3 : 13
6 : 17
0.297
Follow-up duration, months
34.3 ± 12.7
34.5 ± 13.8
29.2 ± 17.0
0.314
Height, cm
162.9 ± 7.4
159.1 ± 8.0
163.3 ± 7.9
0.236
Weight, kg
61.6 ± 11.4
60.0 ± 8.7
61.6 ± 13.5
0.827
BMI, kg/m2
23.3 ± 3.1
23.7 ± 2.7
23.3 ± 3.9
0.931
Isthmus, mm
4.5 ± 2.5
5.2 ± 1.6
8.0 ± 4.2
<0.001
Thyroid volume, cm3
24.7 ± 13.7
29.2 ± 10.6
53.5 ± 27.1
<0.001
Pre-RAI T3, ng/mL
1.98 ± 1.15
1.52 ± 0.39
1.75 ± 0.52
0.241
Pre-RAI free T4, ng/mL
1.95 ± 1.14
1.84 ± 1.59
2.47 ± 1.09
0.165
Pre-RAI TRAb, IU/L
12.24 ± 11.77
7.98 ± 7.82
20.25 ± 20.08
0.030
Pre-RAI TSI, %
305.2 ± 213.8
331.9 ± 184.2
343.6 ± 220.0
0.793
Pre-RAI TPO Ab, IU/mL
267.9 ± 241.8
233.5 ± 264.1
356.8 ± 226.1
0.226
Pre-RAI Tg Ab, IU/mL
786.1 ± 1310.8
337.9 ± 690.2
409.1 ± 840.4
0.247
RAI dose, mCi
11.5 ± 1.5
12.8 ± 2.8
11.3 ± 1.5
0.191
2-hour uptake, %
41.8 ± 21.1
38.2 ± 21.3
54.8 ± 24.3
0.030
24-hour uptake, %
66.1 ± 20.8
61.1 ± 22.7
69.1 ± 22.7
0.524
2-hour/24-hour ratio
0.60 ± 0.21
0.60 ± 0.23
0.80 ± 0.26
0.002
Serum selenium, μg/L
121.0 ± 17.5
108.7 ± 14.9
117.4 ± 15.9
0.101
Serum 25(OH)D, ng/mL
18.0 ± 9.2
22.8 ± 10.5
19.1 ± 7.9
0.471
Data are presented as mean ± SD or number (%). One-way ANOVA and χ2 tests were performed. BMI: body mass index; RAI: radioactive iodine; TRAb: TSH receptor antibody; TSI: thyroid-stimulating immunoglobulin; TPO Ab: thyroperoxidase antibody; Tg Ab: thyroglobulin antibody; 25(OH)D: 25-hydroxycholecalciferol.
